Notably, a previous systematic review comprehensively summarized the applications of classical biomarkers such as CYFRA 21.1, ERCC1, p53, FGFR3, and TATI in bladder cancer diagnosis and prognosis and confirmed their significant advantages and clinical potential in early diagnosis, recurrence monitoring, and individualized treatment (61). Here, ERCC1 is linked to urinary bladder cancer.